Peginterferon lambda for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomised trial

Kandel et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.08.003, ILIAD Cohort B, NCT04354259, Aug 2025
7-point scale -32% improvement lower risk ← → higher risk Peg.. Lambda  ILIAD Cohort B  LATE TREATMENT RCT Is late treatment with peginterferon lambda beneficial? Double-blind RCT 94 patients in multiple countries Worse 7-point scale results with treatment (not stat. sig., p=0.49) c19early.org Kandel et al., Clinical Microbiology a.., Aug 2025 0 0.5 1 1.5 2+ RR
RCT 97 hospitalized COVID-19 patients showing no significant benefit with peginterferon lambda.
Important missing comments or errors? Let us know.
risk of 7-point scale, 31.6% higher, OR 1.32, p = 0.49, treatment 48, control 46, inverted to make OR<1 favor treatment, day 14, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kandel et al., 14 Aug 2025, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 21 authors, trial NCT04354259 (history) (ILIAD Cohort B).
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0